Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor

被引:25
作者
Bonifácio, MJ [1 ]
Vieira-Coelho, MA [1 ]
Soares-da-Silva, P [1 ]
机构
[1] BIAL, Dept Res & Dev, P-4745457 S Mamede Do Coronado, Portugal
关键词
catechol-O-methyltransferase inhibitor; kinetic; liver catechol-O-methyltransferase; BIA; 3-202; Parkinson's disease;
D O I
10.1016/S0014-2999(02)02879-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present study reports the kinetic inhibitory profile of 1-[3,4-dihydroxy-5-nitroplienyl]-2-phenyl-ethanone (BIA 3-202), a novel inhibitor of soluble catechol-O-methyltransferase (COMT) in rat liver. After an oral single dose (30 mg kg(-1)), there was a time-dependent recovery of enzyme activity from 98 +/- 2% inhibition at 30 min to total recovery at 24 It after treatment. The inhibitory effect produced by BIA 3-202 on soluble COMT was reversible after gel filtration of the samples. BIA 3-202 acted as a fast inhibitor of rat liver soluble COMT, interacting immediately with the enzyme after mixing. No differences were observed in the metanephrine formation rates (in nmol mg protein(-1) min(-1)) obtained without and with a 60-min preincubation with 30 nNI of BIA 3-202 (1.30 +/- 0.02 and 1.35 +/- 0.03, respectively). The tight-binding nature of the inhibition produced by BIA 3-202 was evaluated by performing an Ackermann-Potter plot. The true K-i for BIA 3-202, derived from the nonlinear regression analysis, was 0.19 +/- 0.02 nM. In substrate competition studies, an increase in the concentration of adrenaline resulted in a linear increase in IC50 values for BIA 3-202. In conclusion, BIA 3-202 behaves as a reversible, potent and fast tight-binding COMT inhibitor that acts competitively at the substrate binding site of rat liver soluble COMT. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:163 / 170
页数:8
相关论文
共 28 条
[1]  
AXELROD J, 1958, J BIOL CHEM, V233, P702
[2]   New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease [J].
Bonifati, V ;
Meco, G .
PHARMACOLOGY & THERAPEUTICS, 1999, 81 (01) :1-36
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   TIGHT-BINDING INHIBITORS .1. KINETIC-BEHAVIOR [J].
CHA, S .
BIOCHEMICAL PHARMACOLOGY, 1975, 24 (23) :2177-2185
[5]  
GULDBERG HC, 1975, PHARMACOL REV, V27, P135
[7]  
Jost WH, 2000, J NEUROL, V247, P31
[8]   Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease [J].
Kaakkola, S .
DRUGS, 2000, 59 (06) :1233-1250
[9]   DISTRIBUTION OF CATECHOL-O-METHYLTRANSFERASE ENZYME IN RAT-TISSUES [J].
KARHUNEN, T ;
TILGMANN, C ;
ULMANEN, I ;
JULKUNEN, I ;
PANULA, P .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1994, 42 (08) :1079-1090
[10]  
Kurth Matthias, 1998, Neurology, V50, pS3